Through a combination of Supreme Court decisions, pending regulatory changes and proposed legislation, 2007 marked a watershed year for U.S. patent law.
Not since the extension of the patent term for FDA delays in 1988 have the biotechnology and pharmaceutical industries faced such potential and actual fundamental changes to their patent rights.